Raymond James Financial Inc. acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) during the fourth ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - ...

What Happened? Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session ...

Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...

Charles Schwab Investment Management Inc. cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 0.5% in the fourth quarter, according to its most recent 13F filing with the ...

Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.

Lantheus Holdings saw an 18.83% increase in its share price over the past week, driven by recent corporate updates and market trends. The company announced its 2024 earnings, reporting a sales ...

Lantheus Holdings, Inc. (NASDAQ:LNTH), a $6.83 billion market cap leader in the development and commercialization of innovative diagnostic and therapeutic agents, has been the subject of intense ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

Reports Q4 revenue $391.1M, consensus $376.18M. “2024 was a groundbreaking year for Lantheus (LNTH), as our radiodiagnostic, PYLARIFY, reached ...

Explore the exciting world of Lantheus Holdings (NASDAQ: LNTH) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Shares of radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) jumped 19.8% in the morning session after the company delivered strong fourth-quarter 2024 results, with revenue and earnings ...